Table 2 Association between the S100B polymorphisms and risk of IS.
SNPs | Controls (n = 398) | IS patients (n = 396) | AOR (95% CI)† | P † | P BH |
|---|---|---|---|---|---|
rs9722 | |||||
GG | 197 (49.5) | 163 (41.2) | 1.000 (ref) | ||
GA | 175 (44.0) | 186 (47.0) | 1.392 (0.973–1.993) | 0.071 | 0.213 |
AA | 26 (6.5) | 47 (11.9) | 2.172 (1.175–4.014) | 0.013 | 0.095 |
Dominant | 1.507 (1.071–2.123) | 0.019 | 0.095 | ||
Recessive | 1.846 (1.025–3.323) | 0.041 | 0.154 | ||
Additive | 1.371 (1.109–1.694) | 0.003 | 0.045 | ||
rs9984765 | |||||
TT | 190 (47.7) | 176 (44.4) | 1.000 (ref) | ||
CT | 177 (44.5) | 179 (45.2) | 1.290 (0.902–1.845) | 0.163 | 0.348 |
CC | 31 (7.8) | 41 (10.4) | 1.497 (0.817–2.743) | 0.192 | 0.348 |
Dominant | 1.325 (0.941–1.864) | 0.107 | 0.268 | ||
Recessive | 1.320 (0.740–2.354) | 0.347 | 0.377 | ||
Additive | 1.146 (0.927–1.416) | 0.209 | 0.348 | ||
rs2839356 | |||||
TT | 196 (49.2) | 182 (46.0) | 1.000 (ref) | ||
CT | 174 (43.7) | 178 (44.9) | 1.194 (0.837–1.703) | 0.327 | 0.377 |
CC | 28 (7.1) | 36 (9.1) | 1.080 (0.574–2.032) | 0.812 | 0.508 |
Dominant | 1.175 (0.837–1.650) | 0.352 | 0.377 | ||
Recessive | 0.992 (0.539–1.824) | 0.979 | 0.587 | ||
Additive | 1.115 (0.900–1.382) | 0.320 | 0.377 | ||
rs1051169 | |||||
GG | 164 (41.2) | 153 (38.6) | 1.000 (ref) | ||
CG | 178 (44.7) | 186 (47.0) | 1.149 (0.795–1.660) | 0.460 | 0.406 |
CC | 56 (14.1) | 57 (14.4) | 1.152 (0.684–1.942) | 0.595 | 0.406 |
Dominant | 1.150 (0.812–1.627) | 0.432 | 0.406 | ||
Recessive | 1.069 (0.660–1.731) | 0.787 | 0.508 | ||
Additive | 1.064 (0.868–1.304) | 0.551 | 0.406 | ||
rs2186358 | |||||
AA | 328 (82.4) | 336 (84.8) | 1.000 (ref) | ||
AC | 63 (15.8) | 56 (14.2) | 0.876 (0.549–1.398) | 0.579 | 0.406 |
CC | 7 (1.8) | 4 (1.0) | 0.608 (0.130–2.857) | 0.529 | 0.406 |
Dominant | 0.853 (0.543–1.340) | 0.490 | 0.406 | ||
Recessive | 0.621 (0.132–2.910) | 0.545 | 0.406 | ||
Additive | 0.821 (0.580–1.162) | 0.265 | 0.377 | ||
